Lupin has informed about submission of a Press Release as regards receipt of successful completion of the US FDA inspection at the Company's Lupin Bioresearch Centre without any observations. This is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.